Partners and Sponsors

IARC’s Mission: Cancer research for cancer prevention The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization. The objective of the IARC is to promote international collaboration in cancer research. The Agency is inter-disciplinary, bringing together skills in epidemiology, laboratory sciences and biostatistics to identify the causes of cancer so that preventive measures may be adopted and the burden of disease and associated suffering reduced. A significant feature of the IARC is its expertise in coordinating research across countries and organizations; its independent role as an international organization facilitates this activity. The Agency has a particular interest in conducting research in low and middle-income countries through partnerships and collaborations with researchers in these regions. Causes and prevention of cancer Emphasis is placed on elucidating the role of environmental and lifestyle risk factors and studying their interplay with genetic background in population-based studies and appropriate experimental models. This emphasis reflects the understanding that most cancers are, directly or indirectly, linked to environmental factors and thus are preventable. The IARC Monographs Programme is a core element of the Agency’s portfolio of activities, with international expert working groups evaluating the evidence of the carcinogenicity of specific exposures. The Agency is also committed to studying approaches for the early detection of cancer and in evaluating prevention strategies. A global reference for cancer information The IARC has an important role in describing the burden of cancer worldwide, through co-operation with and assistance to cancer registries and in monitoring geographical variations and trends over time. Key publications include the Cancer Incidence in Five Continents series and GLOBOCAN. The classification of human tumours as reported in the WHO “Blue Book” series is an additional resource of value to cancer researchers and clinicians worldwide. In all cases the Agency strives to make its findings available to the widest possible audience. Global cancer biobank One of the products of IARC’s coordinating role is an increasingly important biobank with currently approximately 6 million samples from 600 000 subjects in total. This resource permits the application of innovative laboratory-based methodologies to study the causes, early detection and prevention of cancer through collaborative studies with many international partners. Education and training A core part of the Agency’s mission is education and training of cancer researchers worldwide. This is achieved through fellowships, courses and publications. Priority is given to training researchers from low and middle-income countries in the areas of cancer epidemiology and cancer registration. Producing evidence-based science for global cancer control policies The close working relationship between IARC and its parent organization, WHO, allows the research findings of the Agency to be translated effectively into timely policies for cancer control. This is manifest, for example, in co-operation in terms of reduction in tobacco use, implementation of vaccination against viruses associated with cancer causation, or in assessing the effectiveness of intervention strategies. IARC is not involved directly in implementation of control measures, nor does it conduct research on treatment or care of cancer patients.

Geneva, a dynamic hub of knowledge linking local experts in key industry sectors The Geneva Convention Bureau is proudly supporting the organisation of the World Cancer Congress.

The République et Canton de Genève is proudly supporting the organisation of the World Cancer Congress.

All.Can is a global, multi-stakeholder initiative to inform and generate political and public engagement on the need to improve the efficiency of cancer care by focusing on what really matters to patients and society. Established in 2016, the All.Can initiative brings together a diverse membership base including policymakers, academics, patient organisations, healthcare professionals and industry. All.Can seeks to make sure resources are directed towards achieving better health outcomes while contributing to health systems’ overall sustainability. The initiative aims to identify inefficiencies in cancer care, which they define as anything that doesn't focus on what matters to patients. Through research and collaboration, All.Can highlights best practices and develop policy recommendations to improve cancer care for all.

The Swedish Cancer Society has a vision of a society in which fewer people get cancer and more people are cured or are able to lead long lives, enjoying a good quality of life. Together, we are helping to give more people a better future. Our mission: How we are beating cancer faster together · We enable new discoveries that speed up the work of beating cancer · We help to shorten the path from research results to improved outcomes · We create broad engagement to beat cancer faster together · We use the knowledge and insights of people affected by cancer to develop and improve our work The Swedish Cancer Society is working to ensure that Sweden achieves the following targets by 2030: PREVENTION Fewer people getting cancer. A 30% reduction in preventable cancer. EARLY DETECTION A third of all cancer detected at an earlier stage. CURE 80% surviving a cancer diagnosis. LIVING WELL Everyone living with and after a cancer diagnosis enjoying a good quality of life.

Expertise France, the French public international cooperation agency, designs and implements projects aligned with the Sustainable Development Goals (SDGs) of the 2030 Agenda and France's external action priorities. Despite progress in poverty reduction and access to health and education, global inequalities persist, exacerbated by climate change and emerging conflicts. In this context, public policies are crucial for sustainable development and inequality reduction. Supported by UNITAID, Expertise France is implementing the SUCCESS project, which focuses on combating cervical cancer through secondary prevention. The project targets women at high risk, aiming to prevent cancer progression in those with HPV infections and precancerous lesions by improving HPV detection and treatment. SUCCESS is being implemented in Côte d’Ivoire, Burkina Faso, the Philippines, and Guatemala—regions with limited resources where over 85% of cervical cancer deaths occur.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. To learn more, please visit us on www.Pfizer.com and follow us Social Media.

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases. 

The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are multidisciplinary, global oncology organizations with nearly 45,000 members in over 150 countries. Through research, education, and promotion of high-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

More details will be added soon.

Mission Early is a new multi-stakeholder, global initiative bringing together like-minded individuals, organizations, companies, and existing initiatives who believe in the importance of delivering quality early cancer care, including early detection (screening, referral, and early diagnosis), and early treatment (timely treatment and early-stage treatment).

More details to be added soon

At UE LifeSciences, we believe that early detection of cancer must be affordable, equitable and accessible to all. We’re an award-winning women’s health company that is developing and scaling innovative solutions to fight common cancers in women globally. Our non-invasive and easy to use hand-held tools enable healthcare providers to bring early detection of breast and cervical cancer to the women in their community, where they live and work. Our innovation has received Innovative Health Technology recognition from the World Health Organization and Global Women’s HealthTech Award from the World Bank in 2022. With headquarters in the United States, UE LifeSciences has presence in India and Malaysia.

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, BeiGene is expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030.

Antimicrobial resistance (AMR) accounts for nearly 1.3 million deaths globally and is one of the worst threats facing humanity. One group that is significantly at risk is the cancer community. AMR undermines key advances in cancer care by adversely affecting cancer treatment outcomes and threatening the survival of people living with cancer. As many as 1 in 5 cancer patients undergoing treatment are hospitalized due to infection, and antibiotics are the main line of defense. While such a threat is evident, there is a dearth of data that quantifies this link. Further generation of data would highlight the growing threat and support the cancer community in their efforts of improving outcomes and reducing risk of AMR for cancer patients, globally. The Cancer & AMR Consortium is a partnership among the AMR Action Fund, BD, and UICC quantifying the impact of antimicrobial resistance on cancer patients, and sounding the alarm that infections are undermining the advancements that have been made in oncology. To learn more, visit our webpage.

DeepHealth, a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) provides AI-powered health informatics to empower breakthroughs in care through imaging. The heart of its portfolio of solutions, the DeepHealth OS, is a cloud-native operating system that orchestrates all clinical and operational data to drive value across the enterprise. The portfolio builds on the strengths of RadNet’s existing digital health businesses and products, including eRAD Radiology Information Systems and Image Management Systems, Aidence lung AI, Quantib prostate AI, and DeepHealth breast AI. DeepHealth aims to elevate the role of the radiologist beyond radiology and across the entire care pathway. It empowers all users across the care continuum with personalized workflows to make work easier and more meaningful. DeepHealth leverages advanced AI operational and clinical technologies in breast, lung, brain, and prostate health, leading to increased operational efficiency, clinical confidence, and patient outcomes.

Cancer Awareness Campaigns: Jhpiego work in country programs to conduct community outreach and education campaigns for cervical cancer prevention. The awareness campaigns are targeted to women in the catchment areas where VIA and Cryotherapy services have been set up. Advocacy and awareness campaigns have been conducted in Ghana (in collaboration with Rotary Club), Malawi, Philippines, Thailand, Guyana, etc. Jhpiego also participates in and receives funding support from the Tour of Hope, which raises funds for education and healthcare support for the prevention and treatment of cervical cancer in Asia. Cancer Prevention: Jhpiego provides technical assistance to countries for the introduction and expansion of cervical cancer prevention programs, with a focus on the Single Visit Approach, which combines screening with Visual Inspection with Acetic Acid (VIA), with the offer of Cryotherapy at the same visit. Jhpiego implements comprehensive prevention programs, taking into account advocacy and policies, training, service delivery, referral systems, community education, and monitoring and evaluation. Jhpiego is currently implementing programs Peru, Guyana, Indonesia, Ivory Coast, Mozambique, South Africa, Tanzania, Thailand and the Philippines. Jhpiego has also implemented programs in Ghana and Malawi. Several Cancer Research & Publications. Education & Training: Jhpiego has organized and conducted three Regional VIA and Cryotherapy Clinical Training Courses; two in Asie (Thailand, Philippines) and one in Africa (Malawi). In addition, as a component of ongoing programs, Jhpiego routinely provides VIA and Cryotherapy training and follow up supervision and coaching support for health care providers Ghana, Malawi, Peru, Guyana, Indonesia, Ivory Coast, Mozambique, South Africa, Tanzania, Thailand and the Philippines.